Terns Pharmaceuticals Hits 52-Week High Amid Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Terns Pharmaceuticals Inc saw a price increase of 9.96%, reaching a 52-week high despite the broader market downturn.
The Nasdaq-100 and S&P 500 indices are down 0.45% and 0.47%, respectively, indicating a challenging environment for many stocks.
This performance may reflect investor confidence in Terns Pharmaceuticals, suggesting potential growth opportunities ahead.
Analyst Views on TERN
Wall Street analysts forecast TERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 53.75 USD with a low forecast of 35.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.200
Low
35.00
Averages
53.75
High
60.00
Current: 34.200
Low
35.00
Averages
53.75
High
60.00
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
